The gold standard for monitoring overall glycemia is HbA1c. However, HbA1c has several important limitations, giving more weight to the prior 2 to 3 months rather than short-term glycemic control. In addition, the level of the HbA1c does not reflect the important interpersonal differences in its relationship with mean glucose, and HbA1c is affected by many common clinical conditions (anemia, uremia) that can interfere with the accuracy of its measurement in the laboratory. The development and refinement of continuous glucose monitoring (CGM), a glucose-and patient-centric technology, over the past two decades have permitted the creation of new single and composite metrics, such as the percentage of time in range and the glucose pentagon, respectively, which provide clinically relevant insights into short-term glycemic control. In addition, CGM creates new outcome metrics for clinical management and investigational studies (percentage of time in hypoglycemia, percentage of time in target range) that can accurately and meaningfully report the effects of an intervention, whether that is a drug, a device, or a psychosocial program, and CGM provides the key input to drive algorithm-based insulin delivery. Finally, CGM linked with artificial intelligence permits real-time feedback to patients about modifiable patterns of glycemic excursions.
Introduction
The term "beyond HbA1c" has entered the diabetes lexicon over the past few years. The US Food and Drug Administration (FDA) and the diaTribe Foundation have recently held workshops to explore its meaning. 1, 2 "Beyond HbA1c" has several meanings that include glycometrics (percentage of time in range, percentage of time in hypoglycemia and hyperglycemia, glycemic variability) and patient-reported outcomes (quality of life assessments). Going "beyond HbA1c" means changing the conversation from HbA1c alone to one that is more glucose-centric, and therefore patient-centric. This has become possible because of the increasing use of continuous glucose monitoring (CGM) for patient management and clinical trials. This review describes why the author believes we are rapidly heading to an era where blood glucose monitoring by fingerstick will join urine glucose testing as an interesting historical fact, with a patient's diabetes management based on CGM data.
HbA1c does not reflect clinically important short-term glycemic control
Ever since the completion of the seminal trials in type 1 diabetes mellitus (T1DM), namely the Diabetes Control and Complications Trial (DCCT), 3 and in type 2 diabetes mellitus (T2DM), namely the UK Prospective Diabetes Study (UKPDS), 4 HbA1c has served as the foundation for our understanding of the relationship of glycemic control with micro-and macrovascular complications. These randomized, interventional studies clearly demonstrated that a reduction in HbA1c was associated with a reduction in these complications. Yet, HbA1c is a surrogate marker that reflects mean glucose levels over the previous 2 to 3 months, which obscures important aspects of glycemic control such as the percentage of time within the target range for glucose, the frequency, duration, and severity of hyperglycemia and hypoglycemia, and glycemic variability. Thus, a patient's glycemic control may be excellent, fair or poor with the same HbA1c (Figure 1) . It was not possible to obtain the array of glucometrics in the DCCT and UKPDS because subjects were performing fingerstick glucose measurements only three to four times per day and seven times per day for a week once every 3 months in the DCCT trial and not at all in the UKPDS. The science and practice of glucometrics and pattern analysis became feasible and meaningful once continuous glucose monitoring (CGM) became available in 1999. 5 Continuous glucose monitoring provides up to 288 sensor glucose measurements per day, filling the gaps in glucose levels that even those who perform 10 or more fingerstick blood glucose (BG) measurements per day cannot achieve. Perhaps most importantly, CGM provides valuable data about glucose levels during sleep, because hypoglycemia awareness is dampened during sleep and patients rarely awaken themselves in the middle of the night to routinely check their BG levels. From the standpoint of the healthcare provider, these data are critical for the short-term management of both T1DM and T2DM because they provide actionable information about the efficacy of current therapy and potential ways to modify a patient's treatment based on both the patterns of sensor glucose levels and the known pharmacologic effects of various oral and injectable diabetes medications. Patients understand that HbA1c has a relationship with mean glucose, but they also know that it has little or no relationship with their symptoms on a day-to-day basis. Conversely, patients understand glucose much better because they measure it with fingersticks and recognize that it is directly related to symptoms they may have when their levels are low or high. Recently, an online survey of patients with T1DM, insulin-requiring T2DM, and non-insulinrequiring T2DM found that a glucose-centric metric, namely time in range, was a more important metric than HbA1c as an outcome measure. 2 Wide interpersonal variation in the relationship between HbA1c and mean glucose Over 10 years ago, the A1c-Derived Glucose (ADAG) study demonstrated an excellent correlation between mean sensor glucose levels and HbA1c (R 2 = 0.84) in over 500 subjects with T1DM, T2DM, prediabetes, and those without diabetes. 6 In those with diabetes or prediabetes, this relationship did not differ by age, race, or gender. The table from the ADAG study that relates mean glucose to each percentage HbA1c from 5% to 12% is replicated yearly in the American Diabetes Association's Standards of Care for Diabetes 7 and has become widely accepted in the diabetes community. Some laboratories use the ADAG regression equation to automatically report an "estimated average glucose" derived from the ADAG equation when an HbA1c measurement is performed. What has been underappreciated until recently was the wide confidence limits of mean glucose at each HbA1c level. For example, a person with an HbA1c of 8% could have a mean sensor glucose of anywhere from 147 to 217 mg/dL (8.1-12.1 mmol/L). These confidence limits overlap with those of an HbA1c of 7% (123-185 mg/dL or 6.8-10.3 mmol/L). Thus, individuals with HbA1c values of 7% and 8% could have the same mean glucose. 8 The cause(s) of this individual relationship between mean glucose and HbA1c is multifactorial. The most important factors appear to be mean red blood cell age and glycation rates, both of which may be genetically determined and appear to remain constant over time within an individual. 9 A way to correct HbA1c for red cell age has been proposed by Malka et al. 10 but has not yet been validated clinically.
Hba1c may be inaccurate in a wide range of physiologic and pathologic conditions
There are numerous and frequently encountered clinical conditions that can affect the accuracy of HbA1c measurement by standard laboratory methods, including uremia, anemia, hemoglobinopathies, persistent fetal hemoglobin, pregnancy, hemodialysis, alcohol, and aspirin. Because some of these conditions and/or medication use can vary from month to month and year to year, the relationship between HbA1c and mean glucose can also vary accordingly. Life-long conditions like hemoglobinopathies present a special problem because not all laboratories use HbA1c instruments that are immune to the effects of specific hemoglobinopathies. This is particularly relevant in ethnic groups where sickle cell trait, sickle cell anemia, and thalassemia are prevalent. Most clinicians do not know what method their reference laboratory uses and whether the results can be affected by one or more hemoglobinopathies. The National Glycohemoglobin Standardization Program (NGSP) has an extensive list of laboratory instruments and methods that are and are not affected by specific hemoglobinopathies.
11 It behooves those who treat diabetes to familiarize themselves with the laboratory method used by their hospital laboratory or reference laboratory to understand whether a specific patient's result is an accurate reflection of mean glucose.
Continuous glucose monitoring permits the development of composite metrics for comprehensive understanding of glycemic control
Composite metrics have been used for decades in other medical disciplines but not in diabetology. The APGAR and Glasgow Coma scores are five-and threecomponent metrics, respectively, that reflect important clinical conditions. 12, 13 Several published studies have used composite metrics, usually combining HbA1c with hypoglycemia or mean glucose with hypoglycemia, 14, 15 to display outcomes of intervention studies. We have developed a three-component metric ("hypo-triad") and a five-component metric (comprehensive glucose pentagon [CGP]) to help clinicians, researchers and patients better understand overall glycemic control at a glance. 16, 17 The "hypo-triad" uses frequency, severity and time to numerically and graphically display CGM data. An example of how the "hypo-triad" can provide a robust understanding is shown in Figure 2 , where the CGM data from the first randomized controlled trial of a low glucose suspend (LGS) pump are displayed at baseline and at the end of 3 months in the control group (using a sensor-augmented pump [SAP] ) and in the LGS group. 18 The CGP contains all five key metrics proposed by the Beyond A1C Writing Group. 19 The construction of the CGP has been described in detail elsewhere. 17 Briefly, it plots the time out of range (TOR; which is the reciprocal of time in range), mean sensor glucose, coefficient of variation (CV), intensity of hypoglycemia (the vector composed of the area under the curve [AUC] and duration of hypoglycemia) and intensity of hyperglycemia (the vector composed of the AUC and duration of hyperglycemia) on weighted axes to obtain visual and mathematical reports. There is no HbA1c axis. The central green pentagon is that of a hypothetical person without diabetes (i.e. no TOR, low CV, no hypoglycemia, no hyperglycemia, and a mean sensor glucose <100 mg/dL [5.6 mmol/L]) to which an individual patient can be compared (Figure 3) . The formulas can be easily incorporated into CGM analytics. To date, this has been accomplished for the professional CGM (iPro 2; Medtronic MiniMed, Northridge, CA, USA) reports in China (Liu, Dong, personal communication). The glucose pentagon can be determined as often as clinically relevant (i.e. daily, weekly, monthly, or quarterly). Figure 4 shows an example of CGPs obtained at the time of hospital admission for uncontrolled T2DM and after 6 days of therapy adjustments. The glucose pentagon may also be useful in educating patients because a visual representation of a patient's diabetes control is likely to be more meaningful than a single number like HbA1c.
Non-HbA1c metrics help understand the benefits of advanced diabetes therapies
The diabetes community has reached a consensus that several non-HbA1c metrics are important to understanding glycemic control when assessing the effect of a change in therapy, whether it is for an individual patient or for an interventional study. 20 Times within target ranges (i.e. time below range, time in range, and time above range) are now defined and harmonize with those of the American Diabetes Association/European Association for the Study of Diabetes 21 ( Table 1) . The CV has emerged as the preferred metric to express glycemic variability because the standard deviation is affected by mean glucose and not appropriately applied to data that is not normally distributed. Although there is no "gold standard" target for the percentage of times in range, recent interventional trials provide some guidance about what percentage of time in range is currently achievable. Time in range has been steadily improving, and over 70% seems to be reasonable in patients with T1DM using advanced technologies such as a hybrid closed loop ( Because the road to a fully closed loop (i.e. . 23 These systems display CGM tracings on the pump screen, but the pump takes no independent action. The SAP systems were shown to reduce HbA1c and hypoglycemia, 23 as well as to decrease microalbuminuria after 1 year of use compared with MDI treatment. 31 The next important step in the Medtronic AP journey was the introduction of sensor-integrated pumps (SIP) where the incoming CGM data trigger action by the pump. The first SIP, introduced in 2013 (Medtronic MiniMed 530G and Veo; now supplanted by the Medtronic MiniMed 630G), suspends insulin delivery at a preset threshold (usually 60 mg/dL) for up to 2 hours. Bergenstal et al. 18 showed that this approach reduced nocturnal hypoglycemia without increasing HbA1c. Continuous glucose monitoring metrics can display the outcomes of such trials in a more comprehensive and intuitive way. For example, when the CGM data are analyzed using the "hypotriad" and the CGP, the details of the changes are more clearly seen than with the traditional data displays (Figures 2 and 5) .
artificial pancreas [AP]) is driven by CGM (in conjunction with
Although clinical studies are important in generating evidence for the efficacy of an intervention, real-world data are equally important because they eliminate the inherent selection bias and inclusion and exclusion criteria of clinical trials. Medtronic's CareLink software collects real-world CGM-and pump-generated data. For example, in almost 9 million patient days retrieved from CareLink, there was a 67% decrease in the rate of sensor glucose readings ≤50 mg/dL (≤2.8 mmol/L), from 2% to 0.7%, when the LGS feature was turned on compared with turned off (Medtronic MiniMed, unpublished data, 2016). The Medtronic MiniMed 640G, introduced in 2015, has a predictive algorithm that suspends insulin delivery based on the ambient sensor glucose level and its rate of change, thereby reducing the likelihood that glucose levels will reach a preset low threshold. Several studies have shown significant reductions in low sensor glucose rates using this 20 and Agiostratidou et al. 21 DKA, diabetic ketoacidosis. technology. 25, 26, 32 Real-world data from over 1 million days of use show a reduction of the rate of sensor glucose ≤50 mg/dL (2.8 mmol/L) to 0.4% (Medtronic, data on file, 2017). The most recent step in progress towards the AP is the hybrid closed loop (Medtronic MiniMed 670G) in which basal rates are automatically varied every 5 minutes based on CGM data (auto mode) with the ability to deliver device-determined maximal insulin or no insulin. It is "hybrid" because it still requires the patient to manually bolus for meals and to correct high glucose. Nevertheless, the combination of the ability to vary insulin as basal insulin (from zero to maximal every 5 minutes) based on CGM not only improved HbA1c from 7.4% to 6.9%, but also improved multiple non-HbA1c metrics. 27, 30 Time in target range increased from 64% to >70%, time below target range of <70 mg/ dL (<3.9 mmol/L) decreased by 30% (from 2.6% to 2.0%), and CV decreased from 33% to 30% in adult subjects. 27, 30 The real-world experience in over 3000 patients using the device after its commercial launch in the US has mirrored the pivotal study results. 29 The next steps in AP system development will involve better algorithms that include meal detection and contextual information and, most importantly, improved insulins pharmacokinetics.
Stand-alone CGM, not HbA1c, permits realtime feedback to patients As noted previously, SAP provides real-time feedback to patients with T1DM, permitting them to understand the relationships of their insulin doses, meals, exercise, and other lifestyle choices with glucose levels. The use of CGM in MDI or pump patients results in improvements in glycemic control in patients with T1DM, 22, 24 in T2DM on MDI, 33 and in T2DM patients on oral agents with or without basal insulinorals. 34 However, in these cases, the patients had to intuit the relationship between multiple variables and their glucose levels. The recent launch in the US of Guardian Connect with Sugar.IQ, a collaboration between Medtronic and IBM Watson Health (IBM Corp., Armonk, NY, USA), is the next logical step in helping patients better understand these complex relationships. Real-time CGM data are routed through a smartphone to the cloud, where IBM's cognitive computing identifies glycemic patterns that patients may be unaware of. Through pop-up messages on the patient's phone, Sugar.IQ provides both glycemic and motivational insights to the patient in real-time. In preliminary studies, this type of immediate feedback to patients about glycemic patterns and their relationships with food, insulin doses, exercise, time of day, and day of week has reduced the frequency and severity of glycemic excursions (Medtronic, data on file 2017).
Conclusions
With increasing accuracy and declining cost of CGM, CGM is likely to replace BG, just as BG testing replaced urine glucose testing. This quantum leap in assessing glycemic control should lead to overall better short-term glycemic control, improved quality of life, and reduced long-term micro-and macrovascular outcomes. Although it is unlikely that HbA1c will be abandoned in the near future, ultimately HbA1c will become less important than the glucometrics generated by 
